Skip to content

Compounds · Brain & nerves · Growth hormone stimulation and release

CJC-1295 (with and without DAC)

Full protocol

Modified GRF (1-29), Mod GRF 1-29, CJC-1295 without DAC, CJC-1295 DAC, tetrasubstituted GRF (1-29)

Long-acting synthetic analog of growth hormone-releasing hormone, shown in early studies to raise GH and IGF-1 levels. Not FDA-approved for any use, with no major 2020–2025 trials; banned by WADA and sold as a research chemical, though a 2024 FDA status review opened it to further compounding evaluation without approving it.

0.1–0.2 mg, 1–2× daily

Research score 40/100. Reference only, not a prescription.

  • Growth Hormone Release
  • Muscle Growth
  • Fat Loss
  • Recovery Enhancement
  • Sleep Improvement
US status
Research Chemical
Approval
Not FDA Approved; Prohibited by WADA. Re-evaluated by FDA in 2024 for potential compounding.
Evidence
No active or recent clinical trials. Early-phase studies were conducted prior to 2020 but did not lead to clinical approval.
Research score
40 / 100
Indication
Research Only - No Medical Indication
Origin
Canada
Source category
Brain & Nervous System
Status group
Research chemical

Mechanism

Binds GHRH receptors on the pituitary to trigger GH release via cAMP signaling. The DAC version attaches to serum albumin, extending its half-life from about 30 minutes to 6–8 days for sustained GH/IGF-1 elevation; the non-DAC form (Mod GRF 1-29) acts more briefly.

Safety file

Long-term human safety is unknown. The FDA has flagged cardiac event risk, plus concerns tied to elevated GH/IGF-1, including insulin resistance.

  • Injection site reactions
  • Temporary numbness in extremities
  • Water retention
  • Headache
  • Joint stiffness
  • Increased insulin resistance

Reconstitution

Concentration by vial size and water volume
Vial1 mL water2 mL water
5 mg5 mg/mL2.5 mg/mL
  1. Use bacteriostatic water as the diluent.
  2. Add the water slowly, letting it run down the inside wall of the vial rather than onto the powder.
  3. Swirl gently to mix, then leave it to dissolve. Do not shake.
  4. Give it a few minutes. The finished solution should be clear and colourless.

Full mixing method

Protocol

Route: Subcutaneous

Standard protocol (subcutaneous)

  • 0.1 mg (100 mcg) per dose, once or twice daily, on an empty stomach
  • Because it is short-acting, it is dosed to match pulses: before bed, fasted morning, or post-workout

Best paired

  • Almost always run with Ipamorelin at a matching 0.1 to 0.25 mg (100 to 250 mcg), combined in one syringe, since their short half-lives line up and they amplify each other
  • Run 8 to 12 weeks, 5 on / 2 off

Dosing detail

  • Common dose is 0.1 mg to 0.2 mg (100 to 200 mcg) per shot, once or twice daily.
  • Short half-life (under 2 hours), so time it to pulses and keep it consistent.
  • Empty stomach. Pairs naturally with Ipamorelin in the same syringe.
  • A brief flush after injecting is common.

Duration

  • Run 8 to 12 weeks, 5 on / 2 off, then a break.

Notes

  • Almost always paired with Ipamorelin, since the two are complementary.
  • A brief flush after injecting is common.
  • Inject subcutaneously and rotate sites.

Storage and handling

  • Keep the powdered (lyophilized) vial in a cool, dark place. Refrigerate it for longer-term storage before mixing.
  • Once reconstituted and refrigerated at 2–8 °C away from light, use the vial within 28 days.
  • Do not freeze a reconstituted vial, and keep it away from heat and sunlight.
  • If the solution turns cloudy, develops floating particles, or shows any other sign of degradation, stop using that vial.

Storage rules and when to discard